Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma
Leukemia ( IF 12.8 ) Pub Date : 2017-11-21 , DOI: 10.1038/leu.2017.334 A Gullà , T Hideshima , G Bianchi , M Fulciniti , M Kemal Samur , J Qi , Y-T Tai , T Harada , E Morelli , N Amodio , R Carrasco , P Tagliaferri , N C Munshi , P Tassone , K C Anderson
Leukemia ( IF 12.8 ) Pub Date : 2017-11-21 , DOI: 10.1038/leu.2017.334 A Gullà , T Hideshima , G Bianchi , M Fulciniti , M Kemal Samur , J Qi , Y-T Tai , T Harada , E Morelli , N Amodio , R Carrasco , P Tagliaferri , N C Munshi , P Tassone , K C Anderson
Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma
中文翻译：
精氨酸甲基转移酶5（PRMT5）蛋白具有预后相关性，是多发性骨髓瘤的可治疗靶标
精氨酸甲基转移酶5（PRMT5）蛋白具有预后相关性，是多发性骨髓瘤的可治疗靶标
更新日期：2017-11-21
Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma, Published online: 21 November 2017; doi:10.1038/leu.2017.334
中文翻译：
精氨酸甲基转移酶5（PRMT5）蛋白具有预后相关性，是多发性骨髓瘤的可治疗靶标
精氨酸甲基转移酶5（PRMT5）蛋白具有预后相关性，是多发性骨髓瘤的可治疗靶标
精氨酸甲基转移酶5（PRMT5）蛋白具有预后相关性，是多发性骨髓瘤的可治疗靶标，在线发布：2017年11月21日；doi：10.1038 / leu.2017.334
京公网安备 11010802027423号